Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.

With the stock currently priced at Rs 400.15, Biocon shows a positive trend in today's early trading session on NIFTY MIDCAP 150.

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...